189 results about "Lactulose" patented technology

A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.

A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.

The invention relates to the field of the preparation of functional sugar, and relates to a method for preparing high-purity lactulose. The method for preparing the high-purity lactulose comprises the following steps of: preparing lactose solution at the concentration of 15 to 20 percent; adding a boric acid and sodium hydroxide (NaOH) into the solution, and adjusting a reaction to obtain conversion liquid; performing ion exchange sodium ion (Na<+>)-removing treatment on the conversion liquid; decoloring a granular active carbon column; removing the boric acid from the lactose solution to obtain a lactose solution dry substance with the boric acid content of less than 1 mg / kg; concentrating the lactose solution until the concentration is 50 to 60 percent; separating by using a 10-bed continuous chromatographic separation device; and performing aqueous phase crystallization, wherein the cooling speeds are 0.8 DEG C per hour at the temperature of between 60 and 50 DEG C, 1 DEG C per hour at the temperature of between 50 and 30 DEG C and 1.1 DEG C per hour at the temperature of between 30 and 13 DEG C. The conversion rate of the lactulose can be increased, so that the yield of the lactulose products is greatly improved; granular active carbon is decolored; moving bed chromatographic separation is continuously simulated, so continuous chromatographic separation of the high-purity lactulose can be realized, the purity of the lactulose reaches over 92 percent so as to facilitate aqueous phase crystallization; and the purity can reach over 98 percent due to the aqueous phase crystallization.

The pharmaceutical composition is a combination of hydrolytic lignin with moisture of 55% to 65% consisting of the particles measuring 0.15 mm to 0.55 mm, a 45% to 55% aqueous lactulose solution, and a 50% to 55% aqueous oligosaccharide solution at the following ingredient ratio (weight percent): 10-60 of an aqueous lactulose solution; 10-60 of oligosaccharides; sufficient quantity of hydrolytic lignin. Hydrolytic lignin, lactulose and fructose oligosaccharides are sequentially added and mixed using a rotor blender. The composition is administered orally for no less than 14 days and no more than 30 days, two to four times a day, depending on the patient's weight and age. The composition is used as a medicine for treatment of the gastrointestinal disorders, including bacterial, viral, protozoal enteric infections, food poisoning, acute and chronic hepatitis and cirrhosis, diarrhea, peptic ulcer, Crohn's disease, ulcerative colitis, irritable bowel syndrome, mineral disorders with Ca / Mg deficiency, including osteoporosis and other alterations of the bone formation, as an immunomodulator in atopic dermatitis and immunodeficiency conditions, for protection and recovery of intestinal flora after antibiotic therapy, chemotherapy, and radiotherapy. The result is accelerated achievement of the effect and the enhanced action on the state of intestinal microbiocenosis as well as increased effectiveness of treatment of hepatitis and liver cirrhosis, elimination of undesired adverse effects in clinical usage, and extension of indications, i.e. the extended spectrum of usage in prevention and treatment.